The collaboration aims to increase cervical cancer screening rates in the country.

February 22, 2024

Becton, Dickinson and Company (BD) has partnered with Camtech Health to enhance access to cervical cancer screening in Singapore by introducing a self-collection human papillomavirus (HPV) test for women to use at home.

This initiative aims to address the low screening rates in Singapore, where less than half of the eligible women undergo testing.

The collaboration combines the Camtech Health HPV test for self-collection and the BD Onclarity HPV Assay, which detects 14 high-risk HPV genotypes.

The World Health Organization’s Global Strategy to Accelerate the Elimination of Cervical Cancer has set targets for HPV vaccination, screening coverage, and treatment access by 2030, and this programme supports these goals.

Camtech Health chairman Kuok Meng-Han said: “Making at-home self-collection available is the first step to empowering health and well-being, but making the test easy to use is just as important.

“The Camtech Health HPV test with the Camtech Health app is completed in simple steps and then sent via postage-paid packaging provided in the kit.